6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old
Status:
Completed
Trial end date:
2015-11-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess whether the risk of serious asthma-related events
(asthma-related hospitalizations, endotracheal intubations, and deaths) in children 4-11
years old taking inhaled fluticasone propionate/salmeterol combination is the same as those
taking inhaled fluticasone propionate alone.
Phase:
Phase 4
Details
Lead Sponsor:
GlaxoSmithKline
Collaborator:
Parexel
Treatments:
Fluticasone Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Fluticasone-Salmeterol Drug Combination Salmeterol Xinafoate Xhance